# A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

> **NCT04870112** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 18 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04870112
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-28
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** AstraZeneca has decided to stop further enrollment and the study was terminated when all patients in Part 1 completed their last study visit. No safety issues or clinical concerns however, have been identified for this study. Part 2 was not initiated
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870112, "A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04870112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*